<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00197639</url>
  </required_header>
  <id_info>
    <org_study_id>HSC 10913</org_study_id>
    <secondary_id>R01HD042964</secondary_id>
    <nct_id>NCT00197639</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Indinavir Drug Levels When Boosted With Ritonavir in Thailand</brief_title>
  <official_title>A Pharmacokinetic Study to Assess the Inter-patient Variability of Indinavir Drug Levels When Boosted With Ritonavir in Thai Patients on Highly Active Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harvard School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Harvard School of Public Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study looks at the ways indinavir drug levels, when boosted with ritonavir, may vary
      from patient to patient. The study population are HIV+ Thai individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the inter-individual variability of indinavir drug levels, boosted
      with ritonavir, in Thai patients. Data will be collected in patients participating in the
      randomized study, &quot;Monitoring Highly Active Antiretroviral Therapy (HAART) in HIV-infected
      patients in Thailand (PHPT-3)&quot; (HSC 10668). The first 20 patents in PHPT-3 will have
      steady-state pharmacokinetic sparse sampling performed at pre-dose, and 1, 2.5, 4 and 12
      hours after drug intake 1 and 2 months after initiating IDV/r 400/100 mg, twice daily. IDV/r
      plasma concentrations will be determined by high performance liquid chromatography. This
      spare PK data will be pooled with indinavir concentration data collected within an intensive
      pharmacokinetic studies of IDV/r [Cressey TR, et al 2005, JAC, 55, p1041-44]. Population
      means and variances of indinavir and ritonavir pharmacokinetic parameters were estimated
      using non-linear mixed effects regression models (NONMEM Version VI). The validity of the
      final model was evaluated using a visual predictive check (VPC) and bootstrap re-sampling
      techniques.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">19</enrollment>
  <condition>HIV Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir-boosted indinavir</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected Thai adults
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects enrolled in the parent study, &quot;Monitoring HAART Therapy in HIV-Infected
             Patients in Thailand (PHPT-3)&quot; and agreeing to additional blood sampling and tests.

        Exclusion Criteria:

          -  Current active substance or alcohol abuse

          -  Active opportunistic infection

          -  Chronic malabsorption or diarrhea

          -  Other clinically significant disease

          -  Certain lab values (e.g. hemoglobin &lt; 8.0 mg/dL)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Lallemant</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prapokklao Hospital</name>
      <address>
        <city>Muang</city>
        <state>Chanthaburi</state>
        <zip>22000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakornping Hospital</name>
      <address>
        <city>Mae Rim</city>
        <state>Chiang Mai</state>
        <zip>50180</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonburi Hospital</name>
      <address>
        <city>Muang</city>
        <state>Chonburi</state>
        <zip>20000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phayao Provincial Hospital</name>
      <address>
        <city>Muang</city>
        <state>Phayao</state>
        <zip>56000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Cressey TR, Leenasirimakul P, Jourdain G, Tod M, Sukrakanchana PO, Kunkeaw S, Puttimit C, Lallemant M. Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability. J Antimicrob Chemother. 2005 Jun;55(6):1041-4. Epub 2005 May 9.</citation>
    <PMID>15883177</PMID>
  </reference>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>November 10, 2010</last_update_submitted>
  <last_update_submitted_qc>November 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2010</last_update_posted>
  <keyword>indinavir, HIV, ritonavir, pharmacokinetics, Thailand</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Indinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

